Does a GLP-1 Affect Your Period? Menstrual Cycle Changes, Hormones, and the PCOS Connection

GLP-1 receptor agonists do not act directly on the hypothalamic-pituitary-ovarian (HPO) axis, so they do not change your hormones the way hormonal birth control does. But the rapid weight loss they produce often does change menstrual patterns — sometimes for the better (restoring ovulation in PCOS), sometimes for the worse (temporary cycle irregularity in women with very low body fat), and sometimes via a separate mechanism entirely (the gastric-emptying interaction with oral contraceptives that the FDA flags on the Mounjaro, Zepbound, and Foundayo labels but not on the Wegovy, Ozempic, or Saxenda labels). This article walks through each scenario and the practical guidance.

Do GLP-1s have a direct hormonal effect?

No, not in the sense that estrogen, progesterone, or oral contraceptives do. GLP-1 receptors are present on a number of reproductive tissues — the hypothalamus, the pituitary, the ovary, and the endometrium — and there is active research on what they do there^[5]. But the clinically observed effects of GLP-1 receptor agonists on the menstrual cycle in published trials are dominated by the indirect effect of weight loss, not by a direct endocrine action.

That distinction matters for what to expect: changes in your period on a GLP-1 are usually proportional to the magnitude and speed of your weight loss, not to which specific GLP-1 you take.

The PCOS scenario — restored ovulation

Polycystic ovary syndrome (PCOS) is the single most common reproductive condition in women with obesity, and it is characterized by oligo-ovulation or anovulation, irregular or absent periods, hyperandrogenism, and frequent weight-loss difficulty. Weight loss of even 5-10% of body weight has been shown for decades to restore ovulation in a substantial fraction of women with PCOS^[7].

GLP-1 receptor agonists are increasingly studied for PCOS specifically because they produce the kind of meaningful weight loss that the older first-line PCOS therapies (lifestyle, metformin) struggle to achieve in many patients^[7]. For the full PCOS-specific evidence base (Hollanda Morais 2024 4-RCT meta-analysis, Carmina 2023 80% menstrual-cycle-restoration data, Jensterle 2024 2-year post-discontinuation durability, plus the Cigna IP0206 comorbidity-pathway PA strategy), see our dedicated GLP-1s for PCOS evidence + insurance guide. The published GLP-1 PCOS literature shows:

• Restored menstrual regularity in a majority of women with PCOS who lose >5% body weight on a GLP-1^[5][6].
• Improved ovulation rates compared with baseline, including in women who had been anovulatory before treatment^[4].
• Improved IVF outcomes in pilot trials of obese women with poor response to first-line fertility treatment, when GLP-1 was given before IVF cycles^[4].
• Reduced androgen levels in some studies, though the magnitude is modest and the effect appears to be downstream of weight loss rather than independent.

Practical implication for women with PCOS: if you have PCOS and start a GLP-1, expect your menstrual pattern to change as you lose weight — possibly significantly. Cycles that were skipped or 60+ days long may shorten and normalize. Ovulation that wasn't happening may resume. This means fertility may also return abruptly. If you are not actively trying to conceive, contraception planning is important before the weight loss, not after you find out it worked.

See our GLP-1, pregnancy, PCOS, and fertility article for the full reproductive workup and the IVF / preconception protocol.

The low-body-fat scenario — temporary irregularity

At the other end of the spectrum, women whose body fat percentage drops to very low levels during rapid weight loss sometimes experience temporary menstrual irregularity or amenorrhea (absence of periods). This is not specific to GLP-1s — it's the same physiology that causes functional hypothalamic amenorrhea in athletes and women with energy-deficiency states. The HPO axis suppresses gonadotropin pulses when energy availability falls below a threshold.

This is uncommon in patients on a GLP-1 for weight management because most patients in the registration trials had BMI ≥30 at baseline and a substantial reserve. But it can happen, particularly in patients who:

• Started with a lower BMI (off-label use at BMI <27)
• Are losing weight very rapidly (>2 lb/week sustained)
• Have markedly reduced caloric intake (often a side effect of severe nausea on a GLP-1)
• Combine GLP-1 therapy with very high training volume

If you stop having periods entirely on a GLP-1, that's worth a conversation with your prescriber — both because it can indicate an energy-availability problem and because amenorrhea has long-term bone-health implications.

The contraception interaction

This is the most concrete and best-documented GLP-1 effect on women's health — and it has nothing to do with hormones directly. GLP-1 receptor agonists slow gastric emptying, which can reduce or delay the absorption of any oral medication. For oral contraceptives, the FDA labels approach this differently for injectable vs oral GLP-1s:

Semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda) — no warning

The Wegovy^[1], Ozempic^[9], and Saxenda^[10] labels do not contain a backup-contraception recommendation. Each label acknowledges the general gastric- emptying delay in Section 7.x but explicitly notes the clinical-pharmacology studies showed no clinically relevant reduction in oral contraceptive bioavailability — Saxenda Section 12.3 even reports specific PK data (ethinyl estradiol Cmax −12%, levonorgestrel Cmax −13%, levonorgestrel AUC increased 18%) that did not rise to a clinical recommendation. Most prescribers and major medical societies therefore do not require backup contraception for women on Wegovy, Ozempic, or Saxenda using combined oral contraceptive pills.

Tirzepatide (Mounjaro, Zepbound) — 4-week backup contraception is required

Tirzepatide is the exception. Both the Mounjaro^[11] and Zepbound^[12] prescribing information require a backup-contraception strategy on oral hormonal contraceptives. Per the verbatim Mounjaro Section 7.2 and Zepbound Section 5.2/7.2/8.3 language: “Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation … and for 4 weeks after each dose escalation.” The Mounjaro Section 12.3 clinical-pharmacology data document ethinyl estradiol and norgestimate exposure reductions of roughly 20% after a single 5 mg tirzepatide dose, with substantially greater reductions following dose escalation — the magnitude that crossed the FDA's threshold for an explicit backup-contraception recommendation. See our standalone Mounjaro/Zepbound and birth control deep dive for the full mechanism, the practical 4-week workaround, and why semaglutide and liraglutide differ.

Foundayo (oral orforglipron) — different story^[2]

Foundayo, the new oral non-peptide GLP-1 approved April 2026, carries a more specific oral contraceptive interaction warning in Section 7.1 of its label. The Foundayo label recommends:

• Use a non-oral contraceptive method (barrier, IUD, implant, injectable, or transdermal patch) OR add a barrier method to the oral contraceptive
• For 30 days after starting Foundayo
• For 30 days after each dose increase

The reason Foundayo is treated differently is that as an oral drug it co-localizes with the oral contraceptive in the GI tract during absorption, and the gastric emptying delay has a more direct effect on a co-administered oral drug than on an injectable.

See our GLP-1 drug interaction checker for the full oral contraceptive entry with the FDA citation.

Other reported menstrual changes on a GLP-1

Patient communities and case reports have described a number of additional menstrual changes that are less well-characterized in the formal literature:

• Heavier or lighter periods — usually attributed to weight-related changes in estrogen metabolism (adipose tissue is a peripheral source of estrogen, so significant fat loss can change estrogen balance)
• Worse PMS symptoms in the first few months — possibly related to the GI side effects of the drug overlapping with luteal-phase symptoms
• More cyclical nausea — some patients report that GLP-1 nausea is worse around menstruation
• Cycle shortening or lengthening by a few days — reflecting the HPO axis re-equilibrating to the new weight

These are anecdotal patterns, not labeled effects, and most resolve within a few months as weight loss slows and the body adapts.

What to do if your period changes on a GLP-1

• Track your cycle for 2-3 months before assuming something is wrong. A few short or long cycles in the first months of weight loss is usually normal HPO axis re-equilibration, not pathology.
• Use reliable contraception if you do not want to be pregnant. This is especially important if you have PCOS — restored fertility is a real outcome of weight loss on a GLP-1 and it can happen before you notice your period has normalized.
• If you are on Foundayo, follow the 30-day backup contraception recommendation for the starting dose and after each dose increase.
• If you have not had a period for more than 3 months on a GLP-1 (and you are not pregnant), see your OB/GYN or primary care prescriber. Persistent amenorrhea is worth a workup — it's not a normal effect of GLP-1 therapy and can indicate an underlying issue like functional hypothalamic amenorrhea, thyroid disease, or (less commonly) hyperprolactinemia.
• If you have unusually heavy bleeding, severe pelvic pain, or bleeding between periods — get it worked up. These are not expected GLP-1 effects and should not be attributed to the drug without ruling out other causes.

Pregnancy planning while on a GLP-1

The Wegovy label specifically recommends discontinuing the drug at least 2 months before a planned pregnancy, because of the long elimination half-life (~7 days for semaglutide) and the limited human pregnancy data^[1]. The same 2-month rule is generally applied to tirzepatide. Foundayo, with its much shorter half-life (~36 hours), has a shorter washout. Use our washout calculator to see the residual concentration timeline for any GLP-1.

See our full pregnancy and fertility article for the obstetric safety review, the breastfeeding data, and the preconception checklist.

Bottom line

• GLP-1s do not directly target the menstrual cycle, but the weight loss they produce frequently does.
• PCOS patients often see ovulation restored and menstrual regularity return as they lose weight — meaning fertility can also return unexpectedly.
• Women with very low body fat percentages may experience temporary cycle disruption from energy-availability changes.
• Wegovy, Ozempic, and Saxenda do not have an oral- contraceptive efficacy warning. Mounjaro and Zepbound do — both labels require non-oral or barrier backup contraception for 4 weeks after initiation and for 4 weeks after each dose escalation. Foundayo (oral) carries a 30-day version of the same warning.
• Persistent amenorrhea (>3 months without a period) on a GLP-1 is not a normal effect and warrants a workup.
• Pregnancy planning: discontinue injectable GLP-1s at least 2 months before trying to conceive.

Related research and tools

• What birth control causes weight loss? An evidence review — the contraception-side question that often comes up alongside cycle changes. Two Cochrane reviews anchor the honest answer that no hormonal contraceptive reliably causes meaningful weight loss; Depo-Provera is associated with documented weight gain.
• GLP-1s, pregnancy, PCOS, and women's health — the full obstetric and reproductive review
• GLP-1 drug interaction checker — oral contraceptive entry with FDA citations
• GLP-1 washout calculator — preconception washout timeline
• 17 GLP-1 side effect questions answered
• GLP-1 fatigue, hair loss, and side-effect duration
• Why am I not losing weight on a GLP-1? Plateau guide

Important disclaimer. This article is educational and does not constitute medical advice. Changes in menstrual pattern, fertility planning, and contraception decisions should always be discussed with your prescribing clinician and OB/GYN. If you experience persistent amenorrhea, abnormal bleeding, severe pelvic pain, or suspect pregnancy on a GLP-1, contact your provider promptly.